

CLAIMS

1. Use of nemolizumab in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having prurigo nodularis (PN), in which the subject does not have atopic dermatitis.
- 5 2. Use according to Claim 1, in which the subject has been diagnosed of PN for at least 6 months.
3. Use according to Claim 1 or 2, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.
4. Use according to Claim 1, 2 or 3, in which the subject has prurigo lesions on upper
10 limbs.
5. Use according to any preceding claim, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
6. Use according to any preceding claim, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).
- 15 7. Use according to any preceding claim, in which the nemolizumab is to be administered according to a flat dosing regimen.
8. Use according to any of Claims 1 to 6, in which the nemolizumab is to be administered according to a loading dose regimen.
9. Use according to any preceding claim, in which the nemolizumab is to be administered
20 at a dose of 0.01 mg/kg to 0.1 mg/kg, 0.1 mg/kg to 0.5 mg/kg, 0.5 mg/kg to 1.5 mg/kg, 1.5 mg/kg to 2.5 mg/kg, or 2.5 mg/kg to 10 mg/kg.
10. Use according to any of Claims 1 to 8, in which the nemolizumab is to be administered at a dose of 10 mg, 15 mg, 20 mg, 25 mg, 30 mg, 35 mg, 40 mg, 45 mg, 50 mg, 55 mg, 60 mg, 65 mg, 70 mg, 75 mg, 80 mg, 85 mg, 90 mg.
- 25 11. Use according to any preceding claim, in which the nemolizumab is to be administered by a topical or parenteral route.

12. Use according to any of Claims 1 to 10, in which the nemolizumab is to be administered subcutaneously.
13. Use according to any preceding claim, in which the nemolizumab is to be administered once per week, once every two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.
14. Use of nemolizumab in the manufacture of a medicament for the treatment of skin lesions and pruritus in a subject having prurigo nodularis (PN), in which the medicament comprises within the range of 30 mg to 60 mg of nemolizumab.
15. Use according to Claim 14, in which the subject has been diagnosed of PN for at least 6 months.
16. Use according to Claim 14 or 15, in which the subject has at least 20 nodules on his/her body with a bilateral distribution.
17. Use according to any of Claims 14, 15 or 16, in which the subject has prurigo lesions on upper limbs.
18. Use according to any of Claims 14 to 17, in which the pruritus has been assigned a score of at least 4 on the Numerical Rating Scale (NRS).
19. Use according to any of Claims 14 to 18, in which the pruritus has been assigned a score of at least 7 on the Numerical Rating Scale (NRS).
20. Use according to any of Claims 14 to 19, in which the subject does not have atopic dermatitis.
21. Use according to any of Claims 14 to 20, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject according to a flat dosing regimen.
22. Use according to any of Claims 14 to 20, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject according to a loading dose regimen.
23. Use according to any of Claims 14 to 22, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once per week, once every

two weeks, once every three weeks, once every four weeks, once every five weeks, once every six weeks, once every seven weeks, or once every eight weeks.

24. Use according to any of Claims 14 to 23, which is characterized in that the medicament is used such that the nemolizumab is to be administered to a subject at a dose of 30 mg or 60 mg.

25. Use according to Claim 24, which is characterized in that the medicament is used such that the medicament is to be administered to a subject once every four weeks.

26. Use of nemolizumab in the preparation of a medicament for the treatment of prurigo nodularis (PN), in which the medicament is to be administered to a subject subcutaneously once every four weeks, in which:

- (i) 60 mg of nemolizumab is to be administered first and 30 mg of nemolizumab is to be administered subsequently once every four weeks thereafter, or
- (ii) 60 mg of nemolizumab is to be administered once every four weeks.